Rituximab vs placebo
Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
- OR 0.91 [0.37, 2.24]1 study · 104 participantsVery low